The present study set out to explore several aspects of endogenous circulating AAT as a dynamic biomarker for the risk of developing acute GVHD, with relevance to baseline tissue damage and systemic inflammation, both detrimental to HSCT outcomes. The gene discussed is SERPINA1; the disease is acute graft versus host disease.